SBVA

SBVA, formerly known as SoftBank Ventures Asia, became an independent firm following the spinout from SoftBank Group and now operates from Seoul with a substantially expanded mandate and capital base. The firm is one of the larger early to mid-stage venture investors active in the broader Asian technology ecosystem, with an investment thesis that has tilted heavily toward AI infrastructure and applied AI across enterprise and consumer categories.

The healthcare portion of the portfolio is concentrated in AI and machine learning applied to healthcare, digital health, and health IT, reflecting both the firm’s broader AI emphasis and the strong Korean ecosystem in clinical AI. SBVA backs companies building foundational AI capabilities and applied AI products, with particular interest in teams that can plausibly become category-defining over a multi-year horizon. The portfolio includes companies across the AI stack, and within healthcare the team gravitates toward AI-driven diagnostic, clinical workflow, and drug discovery platforms rather than traditional digital health subscription businesses.

Check sizes typically run from one to five million dollars at entry, with the firm participating from seed through Series C. Geographic footprint covers Korea, broader Asia including Southeast Asia, and selectively the United States and Israel for companies with strong Asian commercial potential. The firm’s independence from SoftBank Group means investment decisions are made on a financial venture basis rather than as part of a strategic mandate, though some of the network advantages from the SoftBank heritage remain accessible.

The team includes senior partners with substantial track records in Asian venture and operating roles, supported by an investment staff distributed across Asian markets. Decision-making moves through investment committee but the firm’s scale and partnership depth allow for reasonably efficient process for prepared founders. Diligence is rigorous on technical depth, market sizing, and execution velocity, with a clear preference for companies that can demonstrate progress on fast cadences.

For founders, SBVA functions as one of the more substantial early to mid-stage Asian venture investors, particularly for AI-driven companies. Useful introductions tend to involve other Asian institutional investors, AI talent networks, and selectively companies in the broader portfolio where commercial collaboration could accelerate growth. Post-investment engagement is moderate; partners typically take board or observer seats and engage at major inflection points, particularly around fundraising, hiring, and international expansion strategy. The firm’s reputation has shifted from corporate venture associations toward an independent AI-focused identity, and founders should engage with the team based on current positioning rather than historical perceptions. For AI in healthcare and digital health founders across Asia who need a credible, well-capitalized regional venture partner that takes AI seriously as a category, SBVA is one of the firms that can plausibly support a multi-round trajectory and bring relevant network to bear at each stage.